Mei Dong

Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity

Zhiqiang Ning, Zhibin Li, Michael Newman et al. · Cancer Chemotherapy and Pharmacology · 2011 · 294 citations

Medicine, Oncology, Pharmacology +13

The type III TGF-β receptor suppresses breast cancer progression

Mei Dong, Tam How, Kellye C. Kirkbride et al. · Journal of Clinical Investigation · 2006 · 256 citations · Full text

Medicine, Molecular Biology, Oncology +16

PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors

Funda Meric‐Bernstam, Argun Akçakanat, Huiqin Chen et al. · Clinical Cancer Research · 2012 · 208 citations · Full text

Medicine, Oncology, Pharmacology +16

Loss of Betaglycan Expression in Ovarian Cancer: Role in Motility and Invasion

Nadine Hempel, Tam How, Mei Dong et al. · Cancer Research · 2007 · 130 citations

Medicine, Cancer Biology, Oncology +17

Loss of type III transforming growth factor β receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression

Kelly J. Gordon, Mei Dong, Elizabeth M. Chislock et al. · Carcinogenesis · 2007 · 125 citations · Full text

Life Sciences, Molecular Biology, Oncology +17